CHMFL-PI3KD-317
目录号 : GC65969CHMFL-PI3KD-317 是一种高效、选择性、可口服的 PI3Kδ 抑制剂,IC50 值为 6 nM,对其选择性是对其他 PIKK 家族的 10-1500 倍,例如 PI3Kα (IC50,62.6 nM),PI3Kβ (IC50,284 nM),PI3Kγ (IC50,202.7 nM),PIK3C2A (IC50,>10000 nM),PIK3C2B (IC50,882.3 nM),VPS34 (IC50,1801.7 nM),PI4KIIIA (IC50,574.1 nM) 和 PI4KIIIB (IC50,300.2 nM)。在 Raji 细胞中,CHMFL-PI3KD-317 抑制 PI3Kδ 介导的 Akt T308 磷酸化,EC50 值为 4.3 nM。CHMFL-PI3KD-317 对癌细胞具有抗增殖作用。
Cas No.:2244992-76-3
Sample solution is provided at 25 µL, 10mM.
CHMFL-PI3KD-317 is a highly potent, selective and orally active PI3Kδ inhibitor, with an IC50 of 6 nM, and exhibits over 10-1500 fold selectivity over other class I, II and III PIKK family isoforms, such as PI3Kα (IC50, 62.6 nM), PI3Kβ (IC50, 284 nM), PI3Kγ (IC50, 202.7 nM), PIK3C2A (IC50, >10000 nM), PIK3C2B (IC50, 882.3 nM), VPS34 (IC50, 1801.7 nM), PI4KIIIA (IC50, 574.1 nM) and PI4KIIIB (IC50, 300.2 nM). CHMFL-PI3KD-317 inhibits PI3Kδ-mediated Akt T308 phosphorylation in Raji cells, with an EC50 of 4.3 nM. CHMFL-PI3KD-317 has antiproliferative effects on cancer cells[1].
CHMFL-PI3KD-317 has antiproliferative effects, with GI50s of 3.5?±?0.8, 4.0?±?0.9, 4.8?±?0.2, 3.3?±?0.2, 3.0?±?0.4 μM against PF382, NALM-6, MV4-11, MOLM-14 and MOLM-13 cells, respectively[1].
CHMFL-PI3KD-317 (Compound 15i; 25, 50 and 100?mg/kg/day, p.o., for 14 days) inhibits the growth of the MOLM14 tumor in mice[1].
CHMFL-PI3KD-317 shows favorable oral bioavailability and acceptable half-life (T1/2?=?3.28?h) in Sprague-Dawley rats[1].
Animal Model: | Female nu/nu mice bearing MOLM-14 tumor xenografts[1] |
Dosage: | 25, 50 and 100?mg/kg/day |
Administration: | P.O. for 14 days |
Result: | Inhibited the growth of the MOLM14 tumor without mortality or obvious weight loss in mice. |
Cas No. | 2244992-76-3 | SDF | Download SDF |
分子式 | C21H24ClN5O3S2 | 分子量 | 494.03 |
溶解度 | 储存条件 | Store at -20°C | |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.0242 mL | 10.1208 mL | 20.2417 mL |
5 mM | 0.4048 mL | 2.0242 mL | 4.0483 mL |
10 mM | 0.2024 mL | 1.0121 mL | 2.0242 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet